Liso-Cel Elicits ORR of 97% in Relapsed/Refractory Follicular Lymphoma

A single administration of lisocabtagene maraleucel provided deep and durable remissions when used as third-line treatment in patients with relapsed or refractory follicular lymphoma, including those with high-risk features.

Related Keywords

France ,Claude Huriez ,Franck Morschhauser ,Transcend ,International Conference On Malignant Lymphoma ,International Conference ,Malignant Lymphoma ,Hospital Claude Huriez ,Ann Arbor ,